Altria Keeps Mum on Marijuana Details — for Now
Here’s the latest thinking from the tobacco giant’s executives.
Tobacco giant Altria Group (NYSE:MO) announced its first-quarter financial results last week, and most investors weren’t too happy with what they saw. Between falling revenue and net income, plunging cigarette shipment volumes, and a reduced dividend from its major investment in beer maker Anheuser-Busch InBev, Altria didn’t get off to the strong start to 2019 that it had wanted to see.
One way that Altria investors hope that the tobacco king will recover from its growth woes is through its recent investments beyond the cigarette industry. In particular, Altria’s $1.8 billion investment in Cronos Group (NASDAQ:CRON) added marijuana to the mix, with all the growth potential that budding market brings to the table. In their most recent quarterly discussion with shareholders, Altria CEO Howard Willard and his fellow executives didn’t have a lot to say about its marijuana strategy, instead preferring to talk about what’s happening with its core tobacco businesses. Here are some of the key points that Willard made about Altria’s overall product vision.
Image source: Getty Images.
1. Let Cronos handle cannabis
As you know, we recently closed the deal with Cronos, and through our board representation, we are significantly exposed to their ideas and obviously provide them with ideas on how to further grow their business in the future. . We’ve obviously been thinking quite proactively on our own and are now thinking with Cronos which strategic moves make sense over the next year. I don’t have anything to talk about today, but our intention in making the investment into Cronos and capitalizing them quite competitively versus the other cannabis companies in this space was really designed to enable them to make the kind of moves that are necessary to build out our leadership position.
Analysts pressed Altria for details on what Cronos Group’s strategy will be, especially in light of moves from Cronos’ rivals to build up exposure to the U.S. market through strategic acquisitions and production facility announcements. Willard doesn’t see any need to front-run Cronos’ developments, remaining confident that Altria’s presence on Cronos’ board will ensure appropriate input from the tobacco giant on the cannabis company’s future moves. Willard did promise, though, to have more to say in the next year or two about marijuana and Altria’s role in the industry.
2. JUUL doesn’t seem to be cannibalizing Marlboro
We have not detected any specific impact of JUUL on Marlboro. I would say that JUUL’s growth continues to be more broadly from the cigarette category generally, and we haven’t seen any specific impact on our brands.
The other, much bigger strategic move Altria recently made was its investment in e-cigarette giant JUUL Labs, which gave the tobacco giant exposure to the leading player in the category. Some have argued that buying a stake in JUUL effectively gives Altria a hedge against declining cigarette use, which showed up dramatically in this quarter’s 14% drop in cigarette shipment volume. Altria doesn’t attribute its Marlboro decline directly to JUUL, but Willard did say that he expects the financial contribution from JUUL to gain in significance in the years to come.
3. Picking cigarette alternatives is a customer choice
With regard to IQOS versus JUUL, I think we ultimately believe that the consumer is going to decide which product most appeals to them. It would not surprise me if some consumers actually engage in trial of both products and then ultimately make a choice between the two or whether they want to stay within the cigarette category.
Amid its wide-ranging strategy, Altria is also waiting to see if the U.S. Food and Drug Administration will let it sell Philip Morris International‘s (NYSE:PM) IQOS heated-tobacco system in the U.S. market. With exclusive U.S. licensing rights, Altria could see a big benefit from having access to IQOS, even though it arguably will go up squarely against JUUL. Willard’s approach to the cannibalization question is a reasonable one, and in the long run, Altria just wants to make sure that it’s involved in whatever products its consumers end up wanting to use.
Look for Altria to bounce back
Altria shareholders haven’t been entirely happy with the setbacks that the tobacco company has seen in recent months. However, with the help of multiple initiatives to bolster growth, Altria has a lot of irons in the fire to help it recover from its latest challenges and regain a long-term growth trajectory.
Here's the latest thinking from the tobacco giant's executives.
Cronos investor Altria in merger talks with fellow tobacco giant Philip Morris
Published August 27, 2019
Altria Group and Philip Morris International are in discussions over a potential all-stock “merger of equals,” the companies confirmed Tuesday.
If the merger comes to fruition, it could have an impact on one of the Canadian cannabis sector’s leading companies.
The investment gave Altria – one of the largest tobacco companies in North America and an investor in alcohol giant Anheuser-Busch InBev – a 45% ownership interest in Cronos.
Altria still has an option to boost its stake to 55% and provide an additional CA$1.4 billion in proceeds for the cannabis company.
Altria also controls a majority of the Canadian company’s board.
Andre Calantzopoulos, CEO of Marlboro parent Philip Morris International, is known to have a cautious approach to the cannabis industry.
Days before Altria announced it was tying up with Cronos last year, Calantzopoulos told Bloomberg, “I don’t think it’s our priority right now to consider cannabis.”
He added that cannabis was “criminal still” in places Virginia-based Philip Morris operates.
Cronos stocks trade as CRON on the Toronto Stock Exchange and the Nasdaq.
Weekly International Marijuana News Delivered Right to Your Inbox!
Altria Group and Philip Morris International are in discussions over a potential all-stock, "merger of equals," the companies announced.